Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer

• Main Authors: Thongprasert S., Permsuwan U., Ruengorn C., Charoentum C., Chewaskulyong B.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-83355175819&partnerID=40&md5=d442a1b1a609d7e2dc0410d388bf1123; http://www.ncbi.nlm.nih.gov/pubmed/22151987; http://cmuir.cmu.ac.th/handle/6653943832/2965
• Institution: Chiang Mai University

Aim: Carboplatin plus paclitaxel is a more costly chemotherapy regimen than cisplatin plus etoposide; however there have been reports of higher efficacy and less toxicity of this regimen. Thus, this study aimed to assess the cost-effectiveness of these two chemotherapy regimens in advanced non-small...